12:54 PM EDT, 09/17/2024 (MT Newswires) -- ORIC Pharmaceuticals ( ORIC ) and OpenBench have entered into a discovery collaboration, the latter said Tuesday.

They plan to apply OpenBench's discovery approach and structure-based machine learning platform to enrich discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities, the firm said.

OpenBench said it will be paid upon the identification of novel small molecule chemotypes and the experimental confirmation that they achieve certain criteria defined by ORIC. In return, ORIC will have exclusive rights to discovered leads and access to OpenBench's screening technology with respect to the target of interest.

Price: 10.24, Change: +0.25, Percent Change: +2.50